UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

Docket No. VI/00-001.CIP.D2

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

invention entitled:

invention entitled: FRONT-LOADING MEDICAL INJECTOR ADAPTED TO RELEASABLY ENGAGE A SYRINGE REGARDLESS OF THE ORIENTATION OF THE SYRINGE WITH RESPECT TO THE INJECTOR								
and inver Mark 1 Edward	rocki,	Mark W.	Hitchins, Kev Robert D. Park	in P. s	Cowan, James A. D	Dedig, Franci	is J. Sciulli, Steven C. Rygg	, Larry J. Fuchs,
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:								
☐ Cor	ntinuat	ion 🗵	Divisional		Continuation-in-	part (CIP)	of prior application No.:	09/777,020
Which is Cor Which is	ntinuat	ion 🗆	Divisional	X	Continuation-in-	part (CIP)	of prior application No.:	09/718,230
☐ Cor	ntinuat	ion 🗆	Divisional		Continuation-in-	part (CIP)	of prior application No.:	
Enclosed	d are:				Application E	ilements		
1.) Filin	ng fee as	calculated and	tran	smitted as describ	ed below		
2. 🗵	2. Specification having 67 pages and including the following:							
á	a. 🛛	Descriptive Title of the Invention						
1	o. 🛛	Cross References to Related Applications (if applicable)						
(c. 🔲	Statement Regarding Federally-sponsored Research/Development (if applicable)						
(d. 🔲	Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix						
(e. 🛛	Background of the Invention						
	f. 🛚	Brief Summary of the Invention						
	g. 🛛	Brief Description of the Drawings (if filed)						
1	n. 🛛	Detailed Description						
	i. 🛛	Claim(s) as Classified Below						
	j. 🛛	Abstract	t of the Disclo	sure				

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. VI/00-001.CIP.D2

Total Pages in this Submission 224

Application Elements (Continued) ☑ Drawing(s) (when necessary as prescribed by 35 USC 113) Number of Sheets a. 🗵 Formal Number of Sheets b. 🗆 Informal ☒ Oath or Declaration ☐ Unexecuted Newly executed (original or copy) a. 🛚 Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only) b. 🗵 ☐ Without Power of Attorney With Power of Attorney c. 🛛 **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b). Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix) ☐ Application Data Sheet (See 37 CFR 1.76) ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included) Computer Readable Form (CRF) Specification Sequence Listing on: ii. Paper c. Statement(s) Verifying Identical Paper and Computer Readable Copy **Accompanying Application Parts** ☐ Copies of IDS Citations Preliminary Amendment 13. ☑ Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 14. Certificate of Mailing **16.** ⊠ ☐ First Class

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. VI/00-001.CIP.D2

Total Pages in this Submission 224

Accompanying Application Parts (Continued)

		Accompanying Application Parts (Continued)
7. 🗵	a <i>i</i>	Additional Enclosures (please identify below):
<i>1</i> . <u>1</u> .		Customer Number and Correspondence Address
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pur
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international 45 days after the date of the filing of must notify the Director of such filing not later than 45 days after the date of the filing of must notify such notice such foreign or international application. A failure of the applicant to provide such notice such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, and the prescribed period shall result in the application being regarded as abandoned, and the prescribed period shall result in the application being regarded as abandoned, and the prescribed period shall result in the application being regarded as a same period shall result in the application being regarded as a same period shall result in the application being regarded as a same period shall result in the application being regarded as a same period shall result in th
		P01ULRG/REV06

Page 3 of 4

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. VI/00-001.CIP.D2

Total Pages in this Submission 224

	-
3	ح
3	8
در	1

cc:

Fee Calculation and Transmittal

CLAIMS AS FILED Fee Rate #Extra #Allowed #Filed For \$0.00 \$18.00 0 - 20 = 17 **Total Claims** \$0.00 \$84.00 0 - 3 = 2 Indep. Claims \$0.00 Multiple Dependent Claims (check if applicable) \$750.00 **BASIC FEE** \$0.00 OTHER FEE (specify purpose) \$750.00 **TOTAL FILING FEE** to cover the filing fee is enclosed. A check in the amount of ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. as filing fee. Charge the amount of ☐ Credit any overpayment. ☐ Charge any additional filing fees required under 37 ¢.F R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the malling of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Signature Gregory L. Br MEDRAD, INC. September 23, 2003 Dated: One Medrad Drive Indianola, PA 15051

<u> </u>				Destar A.		
CERTIFICATE OF	MAIL" (37 CFR 1.10)		Docket No.			
Applicant(s): TROCKI			VI/01-001.CIP.D2			
Serial No.	Filing Date	Examiner		Group Art Unit		
To be assigned	September 23, 2003	To be assigned		To be assigned		
	ADING MEDICAL INJECTOR A					
REGARDLESS OF THE ORIENTATION OF THE SYRINGE WITH RESPECT TO THE INJECTOR						
		Luclated de sumanto				
I hereby certify that the	nis New Divisional Application a	(Identify type of correspondence)	<u>.</u>	-		
is being deposited wi	th the United States Postal Servi	ce "Express Mail Post Office	to Ade	dressee" service under		
37 CFR 1.10 in an e	envelope addressed to: The Com	imissioner of Patents and Tra	adema	irks, wasnington, D.C.		
20231-0001 on	September 23, 2003					
	(Date)			•		
		Katherine A	A. Lark	in		
		(Typed or Printed Name of Person				
		Kacherene a.	S	when -		
		(Signature of Person Mail	ing Corr	espondence)		
		EV 30310	2656119	2		
		("Express Mail" Mailir				
		(Dapress Man		- · · · · · · · · · · · · · · · · · · ·		
				•		
Note: Each paper must have its own certificate of mailing.						

Docket No.: VI/00-001.CIP.D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:)	
	TROCKI et al.)	Aut I Ivita Talka aggiomad
Serial	No.: Unassigned))	Art Unit: To be assigned
Filed:	September 23, 2003))	Examiner: To be assigned
For:	FRONT-LOADING MEDICAL INJECTOR ADAPTED TO RELEASABLY ENGAGE A SYRINGE REGARDLESS OF THE ORIENTATION OF THE SYRINGE WITH RESPECT TO THE INJECTOR))))	

CUSTOMER NUMBER AND CORRESPONDENCE ADDRESS

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Please assign the following customer number (bar code label attached) and correspondence address to the enclosed patent application:

Customer Number: 21140

21140

Bar Code Label:

PATENT TRADEHARK OFFICE

Correspondence Address:

Gregory L. Bradley Medrad, Inc.

One Medrad Drive

Indianola, PA 15051

Phone: (412) 767-2400 x3021

Fax: (412) 767-8899

If there are any questions, please do not hesitate to contact the undersigned

attorney of record.

Dated: September 23, 2003

espectfully submitted,

Gregory L. Bradley Reg. No. 34,299

Medrad, Inc. One Medrad Drive Indianola, PA 15051 (412) 767-2400 x3021

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Mailing Label No. EV303102656US. Date of Deposit: September 23, 2003. I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Katherine A. Larkin

Kacherine a. Lackin